Yucheng Technologies Earnings: Must See for China Investors

Posted under SMALL CAP NEWS by admin on Sunday 31 January 2010 at 12:17 pm

jason shadeJason Shade submits:

Yucheng Technologies Inc. (YTEC) (3.55), saw its stock price cut in half following its dismal earnings report Friday. The provider of IT services and software solutions to the Chinese banking sector missed on both revenues and earnings per share.

The report obviously came as a shock to YTEC investors. However, I found a greater surprise in the comments made by Weidong Hong, Chairman and CEO of YTEC.

Complete Story »


AstraZeneca to Ax 8,000 More Workers: Biotech’s Latest Mishaps

Posted under BIOTECH by admin on Sunday 31 January 2010 at 9:19 am

The Burrill Report submits:

AstraZeneca (AZN) said it will eliminate an additional 8,000 jobs or about 12 percent of its workforce as it seeks to cut costs in the face of declining revenue and lowered its forecast for 2010. The announcement came as the company reported earnings that fell short of expectation. The company said the next five years will be difficult as key products come off-patent. AstraZeneca expects to save $1.8 billion a year as a result of the cuts by 2014, but would take a $2 billion restructuring charge. It also announced it would buy back up to $1 billion worth of its own stock.

Pfizer (PFE) said it has withdrawn its application with the U.S. Food and Drug Administration to expand indications for its pain drug Lyrica to include the adjunctive treatment of generalized anxiety disorder. Lyrica is approved to treat epileptic seizures, fibromyalgia and nerve pain. The decision came as part of an overhaul of Pfizer’s product pipeline in the wake of its acquisition of Wyeth. The company announced it was discontinuing 100 development programs. Click here for more.
Spectrum Pharmaceuticals (SPPI) said that it has met with the U.S. Food and Drug Administration regarding its supplemental application to market its experimental injectible drug for colorectal cancer that has spread. The FDA in October told the company it wanted more data on Fusilev (levoleucovorin) before it would approve the drug. The Irvine, California-based company expects to submit the data in the third quarter of 2010. The FDA did not request any additional efficacy studies.
Spectrum Pharmaceuticals said it has terminated its development program for Ozarelix, an experimental drug to treat benign prostate hypertrophy or BPH. The company said the decision will allow it to save $40 million in clinical trials and other related costs. The company said those funds will be used to advance other programs that have the greatest likelihood of commercial success in providing patients with more effective treatment options. Spectrum said the move was part of an effort to streamline and prioritize its portfolio. Ozarelix, a luteinizing hormone-releasing hormone antagonist, was in late stage trials for the treatment of benign prostatic hypertrophy. However, the mixed results of the company’s earlier mid-stage study and the recently announced failure of AEterna Zentaris’s (AEZS) large, late-stage, registrational trial of cetrorelix (another LHRH antagonist) in BPH did not support continued development in this indication.
Sepracor (SEPR) said the U.S. Food and Drug Administration now anticipates completing its review of its application to market its experimental drug Stedesa (eslicarbazepine acetate) on April 30, three-months later than originally expected. The delay follows additional data the Marlborough, Massachusetts-based company’s submitted in response to a request from the agency in November. Stedesa is a novel, voltage-gated sodium channel blocker to treat patients who suffer from epileptic seizures.
A study by researchers at Pfizer is raising questions about rival GlaxoSmithKline’s (GSK) anti-aging drugs in development, Forbes reported. In the Journal of Biological Chemistry, Pfizer scientists say that resveratrol and other drugs developed by Sirtris Pharmaceuticals, GSK’s $720 million acquisition in 2008, fail to hit their intended SIRT1 enzyme. They say earlier findings may be due to “an experimental artifact.” Researchers at Amgen (AMGN) announced similar findings in 2009. In 2007 Sirtris reported that its compound SRT1720 lowered blood sugar in diabetic mice. But Forbes says when Pfizer researchers tried to repeat the experiment, low doses of the experimental drug had no effect on blood sugar and the mice gained weight. High doses of the drug, they say, killed three of eight mice.
Theravance (THRX) said the U.S. Food and Drug Administration notified it that the company’s response to the agency’s request for additional data for its application to market telavancin as a treatment for nosocomial pneumonia is still incomplete. In November 2009, the agency requested additional data on telavancin, a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus or MRSA. The drug, marketed as Vibativ, is approved in the United States and in Canada for the treatment of adult patients with certain complicated skin and skin structure infections. The FDA letter noted that, "While we acknowledge that additional mortality data and analyses have been provided to support pooling the two phase 3 clinical trials, even if this is acceptable, the two pooled studies would equate to only one adequate and well-controlled trial and would not constitute substantial evidence of efficacy. The adequacy and similarity of populations across studies for the purposes of pooling has not yet been determined, and is a review issue." The FDA encouraged Theravance to request a meeting to discuss the issues. However, there was no guidance provided regarding the primary clinical efficacy endpoint suitable for approval, the size or number of additional studies required, or statistical methods for evaluation of clinical results.

Complete Story »


AstraZeneca to Ax 8,000 More Workers: Biotech’s Latest Mishaps

Posted under BIOTECH by admin on Sunday 31 January 2010 at 9:19 am

The Burrill Report submits:

AstraZeneca (AZN) said it will eliminate an additional 8,000 jobs or about 12 percent of its workforce as it seeks to cut costs in the face of declining revenue and lowered its forecast for 2010. The announcement came as the company reported earnings that fell short of expectation. The company said the next five years will be difficult as key products come off-patent. AstraZeneca expects to save $1.8 billion a year as a result of the cuts by 2014, but would take a $2 billion restructuring charge. It also announced it would buy back up to $1 billion worth of its own stock.

Pfizer (PFE) said it has withdrawn its application with the U.S. Food and Drug Administration to expand indications for its pain drug Lyrica to include the adjunctive treatment of generalized anxiety disorder. Lyrica is approved to treat epileptic seizures, fibromyalgia and nerve pain. The decision came as part of an overhaul of Pfizer’s product pipeline in the wake of its acquisition of Wyeth. The company announced it was discontinuing 100 development programs. Click here for more.
Spectrum Pharmaceuticals (SPPI) said that it has met with the U.S. Food and Drug Administration regarding its supplemental application to market its experimental injectible drug for colorectal cancer that has spread. The FDA in October told the company it wanted more data on Fusilev (levoleucovorin) before it would approve the drug. The Irvine, California-based company expects to submit the data in the third quarter of 2010. The FDA did not request any additional efficacy studies.
Spectrum Pharmaceuticals said it has terminated its development program for Ozarelix, an experimental drug to treat benign prostate hypertrophy or BPH. The company said the decision will allow it to save $40 million in clinical trials and other related costs. The company said those funds will be used to advance other programs that have the greatest likelihood of commercial success in providing patients with more effective treatment options. Spectrum said the move was part of an effort to streamline and prioritize its portfolio. Ozarelix, a luteinizing hormone-releasing hormone antagonist, was in late stage trials for the treatment of benign prostatic hypertrophy. However, the mixed results of the company’s earlier mid-stage study and the recently announced failure of AEterna Zentaris’s (AEZS) large, late-stage, registrational trial of cetrorelix (another LHRH antagonist) in BPH did not support continued development in this indication.
Sepracor (SEPR) said the U.S. Food and Drug Administration now anticipates completing its review of its application to market its experimental drug Stedesa (eslicarbazepine acetate) on April 30, three-months later than originally expected. The delay follows additional data the Marlborough, Massachusetts-based company’s submitted in response to a request from the agency in November. Stedesa is a novel, voltage-gated sodium channel blocker to treat patients who suffer from epileptic seizures.
A study by researchers at Pfizer is raising questions about rival GlaxoSmithKline’s (GSK) anti-aging drugs in development, Forbes reported. In the Journal of Biological Chemistry, Pfizer scientists say that resveratrol and other drugs developed by Sirtris Pharmaceuticals, GSK’s $720 million acquisition in 2008, fail to hit their intended SIRT1 enzyme. They say earlier findings may be due to “an experimental artifact.” Researchers at Amgen (AMGN) announced similar findings in 2009. In 2007 Sirtris reported that its compound SRT1720 lowered blood sugar in diabetic mice. But Forbes says when Pfizer researchers tried to repeat the experiment, low doses of the experimental drug had no effect on blood sugar and the mice gained weight. High doses of the drug, they say, killed three of eight mice.
Theravance (THRX) said the U.S. Food and Drug Administration notified it that the company’s response to the agency’s request for additional data for its application to market telavancin as a treatment for nosocomial pneumonia is still incomplete. In November 2009, the agency requested additional data on telavancin, a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus or MRSA. The drug, marketed as Vibativ, is approved in the United States and in Canada for the treatment of adult patients with certain complicated skin and skin structure infections. The FDA letter noted that, "While we acknowledge that additional mortality data and analyses have been provided to support pooling the two phase 3 clinical trials, even if this is acceptable, the two pooled studies would equate to only one adequate and well-controlled trial and would not constitute substantial evidence of efficacy. The adequacy and similarity of populations across studies for the purposes of pooling has not yet been determined, and is a review issue." The FDA encouraged Theravance to request a meeting to discuss the issues. However, there was no guidance provided regarding the primary clinical efficacy endpoint suitable for approval, the size or number of additional studies required, or statistical methods for evaluation of clinical results.

Complete Story »


What the Uncertainty Surrounding Healthcare Reform Means for Follow-On Biologics

Posted under BIOTECH by admin on Sunday 31 January 2010 at 9:19 am

The Burrill Report submits:

As President Barack Obama delivered his State of the Union Address, healthcare reform legislation, as one Senator described, was on life support. The Democrats, losing their super majority in the Senate, say they are not ready to pull the plug on the bill, but as of now, the path forward is unclear.
We spoke to Jim Greenwood, president and CEO of the Biotechnology Industry Organization, about the uncertainty surrounding healthcare reform, what it means for such issues as follow-on biologics, and what the industry’s policy agenda looks like for 2010.

Complete Story »


What the Uncertainty Surrounding Healthcare Reform Means for Follow-On Biologics

Posted under BIOTECH by admin on Sunday 31 January 2010 at 9:19 am

The Burrill Report submits:

As President Barack Obama delivered his State of the Union Address, healthcare reform legislation, as one Senator described, was on life support. The Democrats, losing their super majority in the Senate, say they are not ready to pull the plug on the bill, but as of now, the path forward is unclear.
We spoke to Jim Greenwood, president and CEO of the Biotechnology Industry Organization, about the uncertainty surrounding healthcare reform, what it means for such issues as follow-on biologics, and what the industry’s policy agenda looks like for 2010.

Complete Story »


Duke Energy Goes Solar (A Little)

Posted under ALTERNATIVE ENERGY by admin on Sunday 31 January 2010 at 9:19 am

John Lounsbury submits:

Michael Ziegler, at photovoltaik-guide.de, reports that Duke Energy (DUK) has acquired the Blue Wing Solar Project from juwi solar Inc., based in Boulder, CO. The Blue Wing project is situated in San Antonio, TX and all output will be sold to San Antonio-based CPS Energy. CPS is one of the largest municipality-owned utilities in the U.S.. First Solar (FSLR) thin film solar panels will be used in the project, which will have an output of 14 megawatts.

This the first major solar power venture for Duke and is expected to come on line by the end of 2010. When generation starts, solar will be only about 1.4% of Duke’s renewable power output. By the end of the year Duke expects to have nearly 1,000 megawatts of wind generation in operation.

Complete Story »


Duke Energy Goes Solar (A Little)

Posted under ALTERNATIVE ENERGY by admin on Sunday 31 January 2010 at 9:19 am

John Lounsbury submits:

Michael Ziegler, at photovoltaik-guide.de, reports that Duke Energy (DUK) has acquired the Blue Wing Solar Project from juwi solar Inc., based in Boulder, CO. The Blue Wing project is situated in San Antonio, TX and all output will be sold to San Antonio-based CPS Energy. CPS is one of the largest municipality-owned utilities in the U.S.. First Solar (FSLR) thin film solar panels will be used in the project, which will have an output of 14 megawatts.

This the first major solar power venture for Duke and is expected to come on line by the end of 2010. When generation starts, solar will be only about 1.4% of Duke’s renewable power output. By the end of the year Duke expects to have nearly 1,000 megawatts of wind generation in operation.

Complete Story »


Ferrari to Show Its Hybrid

Posted under ALTERNATIVE ENERGY by admin on Sunday 31 January 2010 at 9:19 am

Greentech Media submits:

The real news in electric vehicles last week was the official unveiling of the hybrid version of the Ferrari 599 GTB Fiorano (FIATY.PK) (as reported by All Cars Electric). The 599 in the model name refers to the 620 horsepower 5.99 liter V-12 engine, now augmented by an electric motor, a lithium-ion battery pack and a flywheel-powered Kinetic Energy Recovery System (KERS).

The hybrid development was spurred by the cry of cash-strapped Ferrari owners trying to get a few more miles per gallon. And this Ferrari delivers — with 11.75 miles per gallon, up from the usual 8.7 miles per gallon. The masters of Maranello strike again.

Complete Story »


Ferrari to Show Its Hybrid

Posted under ALTERNATIVE ENERGY by admin on Sunday 31 January 2010 at 9:19 am

Greentech Media submits:

The real news in electric vehicles last week was the official unveiling of the hybrid version of the Ferrari 599 GTB Fiorano (FIATY.PK) (as reported by All Cars Electric). The 599 in the model name refers to the 620 horsepower 5.99 liter V-12 engine, now augmented by an electric motor, a lithium-ion battery pack and a flywheel-powered Kinetic Energy Recovery System (KERS).

The hybrid development was spurred by the cry of cash-strapped Ferrari owners trying to get a few more miles per gallon. And this Ferrari delivers — with 11.75 miles per gallon, up from the usual 8.7 miles per gallon. The masters of Maranello strike again.

Complete Story »


Wild Weekly Wrap Up: Gradually Getting Longer

Posted under GOLD AND PRECIOUS METALS by admin on Sunday 31 January 2010 at 5:17 am

Phil Davis submits:

Another week another 100 points lower.

Yep, that’s all it was, we lost all of 100 points more than last week, when we fell from 10,725 to 10,172 (553 points) and this week we dropped from Friday’s Dow close of 10,172 all the way down to 10,067. Yet you would think the world had come to an end to hear the media and the traders freaking out. I’m not going to try to explain it, I can’t. Maybe it’s because going into last week we were very bearish but, starting on the 22nd, we let ourselves finally get a little more bullish AND THE MARKET BETRAYED US!

Complete Story »


Next Page »
zinwave Wordpress Theme